SpliSense

About SpliSense

SpliSense is focused on developing transformative RNA-based treatments using Antisense Oligonucleotides (ASOs) to target the root cause of pulmonary diseases, restoring and modifying protein functionality to address untreatable conditions.

Products & Services

SPL84:A program under development for pulmonary disease treatment.

SPL5AC:A therapeutic candidate in the pipeline for pulmonary conditions.

SPL23:A program focused on addressing pulmonary health issues.

Additional Opportunities:Other potential therapeutic solutions in the pipeline.

SPL84-23-1

SPL5

SPL5B

SPL23-2

Specialties

RNA-based therapies Antisense Oligonucleotides (ASOs) Pulmonary disease treatment Cystic Fibrosis Muco-Obstructive Pulmonary Diseases Idiopathic Pulmonary Fibrosis (IPF) Pulmonary diseases Cystic fibrosis Idiopathic pulmonary fibrosis (IPF)

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Grant T: - FT: Grant	A: 13000000 MR: - FA: up to $13 Million FAN: 13000000	D: 2026-06-16 FD: 2026-06-16	1 investors
2	RT: Grant or Investment (unspecified round) T: - FT: Grant or Investment (unspecified round)	A: 8500000 MR: - FA: up to $8.5 million FAN: 8500000	D: 2024-04-03 FD: 2024-04-03	1 investors

Grant Latest

2026-06-16

$13.0M

1 investor (Pro only)

Grant or Investment (unspecified round) 2024-04-03

$8.5M

View 1 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

B

Batsheva Kerem

G

Gili Hart

CEO

B

Batsheva Kerem

CSO & Scientific Founder

E

Efrat Ozeri Galai

SVP Research & Translation

A

Asaf Cohen

SVP CMC & Operations

L

Lital Friedman

VP Clinical & Regulatory Affairs

View 9 more team members with Pro

Unlock Full Team Directory

Recent News

SpliSense Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised